Details for: MAD1L1
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 6.31rCSI 11.07%PRS 52.16
-
CSI 6rCSI 33.9%PRS 45.28
-
CSI 4.92rCSI 3.7%PRS 65.61
-
CSI 4.89rCSI 3.92%PRS 80.62
-
CSI 4.77rCSI 19.25%PRS 59.14
-
CSI 4.28rCSI 15.4%PRS 40.52
-
CSI 4.21rCSI 9.4%PRS 67.95
-
CSI 4.17rCSI 11.96%PRS 79.93
-
CSI 4.12rCSI 10.46%PRS 49.67
-
CSI 3.97rCSI 4.94%PRS 71.03
-
CSI 3.86rCSI 3.72%PRS 81.81
-
CSI 3.73rCSI 2.84%PRS 73.15
-
CSI 3.64rCSI 6.43%PRS 41.12
-
CSI 3.43rCSI 3.5%PRS 73.32
-
CSI 3.41rCSI 2.53%PRS 73.54
-
CSI 3.3rCSI 2.3%PRS 71.2
-
CSI 3.18rCSI 2.63%PRS 62.2
-
CSI 3.05rCSI 2.78%PRS 74.9
-
CSI 3.01rCSI 2.78%PRS 79.76
-
CSI 2.95rCSI 2.06%PRS 62.87
-
CSI 2.89rCSI 1.7%PRS 77.56
-
CSI 2.88rCSI 2.15%PRS 75.37
-
CSI 2.81rCSI 1.95%PRS 75.4
-
CSI 2.78rCSI 2.98%PRS 59.44
-
CSI 2.77rCSI 1.99%PRS 74.59
-
CSI 2.65rCSI 4.23%PRS 52.92
-
CSI 2.62rCSI 5.99%PRS 60.01
-
CSI 2.58rCSI 3.14%PRS 67.71
-
CSI 2.56rCSI 1.7%PRS 80.39
-
CSI 2.5rCSI 14.39%PRS 59.02
-
CSI 2.48rCSI 3%PRS 68.96
-
CSI 2.45rCSI 2.41%PRS 76.03
-
CSI 2.39rCSI 5.35%PRS 42.89
-
CSI 2.38rCSI 3.25%PRS 51.99
-
CSI 2.38rCSI 3.92%PRS 65.59
-
CSI 2.37rCSI 8.87%PRS 52.32
-
CSI 2.35rCSI 1.74%PRS 52.8
-
CSI 2.35rCSI 1.58%PRS 73.33
-
CSI 2.34rCSI 3.84%PRS 49.5
-
CSI 2.34rCSI 3.7%PRS 62.36
-
CSI 2.33rCSI 2.04%PRS 70
-
CSI 2.3rCSI 2.86%PRS 40.16
-
CSI 2.25rCSI 3.9%PRS 50.36
-
CSI 2.24rCSI 6.6%PRS 63.34
-
CSI 2.23rCSI 2.55%PRS 78.97
-
CSI 2.2rCSI 3.25%PRS 65.54
-
CSI 2.16rCSI 2.01%PRS 60.64
-
CSI 2.11rCSI 4.24%PRS 49.29
-
CSI 2.11rCSI 1.66%PRS 66.85
-
CSI 2.07rCSI 6.94%PRS 45.57
-
CSI 2rCSI 4%PRS 77.85
-
CSI 2rCSI 1.58%PRS 47.09
-
CSI 1.99rCSI 3.5%PRS 57.18
-
CSI 1.94rCSI 1.69%PRS 70.91
-
CSI 1.92rCSI 1.56%PRS 61.51
-
CSI 1.92rCSI 4.23%PRS 64.47
-
CSI 1.9rCSI 11.85%PRS 52.17
-
CSI 1.89rCSI 2.37%PRS 70.63
-
CSI 1.87rCSI 3.5%PRS 48.66
-
CSI 1.86rCSI 2.09%PRS 76.57
-
CSI 1.82rCSI 5.7%PRS 43.64
-
CSI 1.76rCSI 1.63%PRS 61.67
-
CSI 1.75rCSI 2.39%PRS 62.01
-
CSI 1.73rCSI 3.1%PRS 59.28
-
CSI 1.72rCSI 1.58%PRS 69.03
-
CSI 1.7rCSI 2.6%PRS 75.87
-
CSI 1.7rCSI 1.5%PRS 65.62
-
CSI 1.68rCSI 1.94%PRS 53.42
-
CSI 1.67rCSI 1.44%PRS 65.1
-
CSI 1.66rCSI 3.37%PRS 39.76
-
CSI 1.63rCSI 4.67%PRS 72
-
CSI 1.63rCSI 2.24%PRS 79.98
-
CSI 1.62rCSI 1.94%PRS 79.78
-
CSI 1.58rCSI 3.87%PRS 53.97
-
CSI 1.58rCSI 1.52%PRS 50.73
-
CSI 1.57rCSI 2.23%PRS 56.41
-
CSI 1.55rCSI 2.47%PRS 52.53
-
CSI 1.53rCSI 3.17%PRS 57.41
-
CSI 1.52rCSI 3.97%PRS 60.06
-
CSI 1.5rCSI 3.88%PRS 55.16
-
CSI 1.47rCSI 4.07%PRS 55.98
-
CSI 1.47rCSI 2.11%PRS 69.7
-
CSI 1.46rCSI 1.91%PRS 73.81
-
CSI 1.45rCSI 2.24%PRS 67.92
-
CSI 1.43rCSI 1.95%PRS 84.57
-
CSI 1.43rCSI 2.15%PRS 64.25
-
CSI 1.41rCSI 1.09%PRS 60.55
-
CSI 1.41rCSI 2.04%PRS 76.19
-
CSI 1.38rCSI 3.3%PRS 61.39
-
CSI 1.38rCSI 1.05%PRS 74.07
-
CSI 1.38rCSI 1.65%PRS 41.89
-
CSI 1.36rCSI 3.15%PRS 49.38
-
CSI 1.3rCSI 1.98%PRS 69.67
-
CSI 1.28rCSI 1.65%PRS 43.29
-
CSI 1.28rCSI 4.09%PRS 57.71
-
CSI 1.25rCSI 2.02%PRS 44.19
-
CSI 1.24rCSI 1.78%PRS 50.1
-
CSI 1.18rCSI 28.25%PRS 41.19
-
CSI 1.12rCSI 2.47%PRS 46.49
-
CSI 1.07rCSI 1.64%PRS 69.18
-
CSI 0.2rCSI 1.2%PRS 69.8%
-
CSI 0.2rCSI 1.2%PRS 76.2%
-
CSI 0.3rCSI 2.9%PRS 86.2%
-
CSI 0.3rCSI 5.9%PRS 51.2%
-
CSI 0.3rCSI 1.7%PRS 69.4%
-
CSI 0.4rCSI 2.1%PRS 87.8%
-
CSI 0.4rCSI 8.1%PRS 52.5%
-
CSI 0.5rCSI 2.3%PRS 59.6%
-
CSI 0.5rCSI 4.2%PRS 53.5%
-
CSI 0.6rCSI 1.9%PRS 46.2%
-
CSI 0.6rCSI 1.7%PRS 51.4%
-
CSI 0.7rCSI 1.9%PRS 71.7%
-
CSI 0.7rCSI 3.3%PRS 50.8%
-
CSI 0.8rCSI 2.9%PRS 42.9%
-
CSI 0.8rCSI 1.4%PRS 42.1%
-
CSI 0.9rCSI 4.5%PRS 72.7%
-
CSI 0.9rCSI 5.3%PRS 43.4%
-
CSI 0.9rCSI 1.7%PRS 70.8%
-
CSI 0.9rCSI 2.3%PRS 58.6%
-
CSI 1.0rCSI 22.8%PRS 42.1%
-
CSI 1.0rCSI 1.6%PRS 49.8%
-
CSI 1.0rCSI 1.5%PRS 56.5%
-
CSI 1.0rCSI 3.2%PRS 58.7%
-
CSI 1.0rCSI 2.1%PRS 62.2%
-
CSI 1.0rCSI 2.5%PRS 40.7%
-
CSI 1.1rCSI 1.6%PRS 69.2%
-
CSI 1.1rCSI 2.5%PRS 46.5%
-
CSI 1.2rCSI 28.3%PRS 41.2%
-
CSI 1.2rCSI 1.8%PRS 50.1%
-
CSI 1.3rCSI 2.0%PRS 44.2%
-
CSI 1.3rCSI 4.1%PRS 57.7%
-
CSI 1.3rCSI 1.7%PRS 43.3%
-
CSI 1.3rCSI 2.0%PRS 69.7%
-
CSI 1.4rCSI 3.2%PRS 49.4%
-
CSI 1.4rCSI 1.7%PRS 41.9%
-
CSI 1.4rCSI 1.1%PRS 74.1%
-
CSI 1.4rCSI 3.3%PRS 61.4%
-
CSI 1.4rCSI 2.0%PRS 76.2%
-
CSI 1.4rCSI 1.1%PRS 60.6%
-
CSI 1.4rCSI 2.2%PRS 64.3%
-
CSI 1.4rCSI 2.0%PRS 84.6%
-
CSI 1.5rCSI 2.2%PRS 67.9%
-
CSI 1.5rCSI 1.9%PRS 73.8%
-
CSI 1.5rCSI 2.1%PRS 69.7%
-
CSI 1.5rCSI 4.1%PRS 56.0%
-
CSI 1.5rCSI 3.9%PRS 55.2%
-
CSI 1.5rCSI 4.0%PRS 60.1%
-
CSI 1.5rCSI 3.2%PRS 57.4%
-
CSI 1.6rCSI 2.5%PRS 52.5%
-
CSI 1.6rCSI 2.2%PRS 56.4%
-
CSI 1.6rCSI 1.5%PRS 50.7%
-
CSI 1.6rCSI 3.9%PRS 54.0%
-
CSI 1.6rCSI 1.9%PRS 79.8%
-
CSI 1.6rCSI 2.2%PRS 80.0%
-
CSI 1.6rCSI 4.7%PRS 72.0%
-
CSI 1.7rCSI 3.4%PRS 39.8%
-
CSI 1.7rCSI 1.4%PRS 65.1%
-
CSI 1.7rCSI 1.9%PRS 53.4%
-
CSI 1.7rCSI 1.5%PRS 65.6%
-
CSI 1.7rCSI 2.6%PRS 75.9%
-
CSI 1.7rCSI 1.6%PRS 69.0%
-
CSI 1.7rCSI 3.1%PRS 59.3%
-
CSI 1.8rCSI 2.4%PRS 62.0%
-
CSI 1.8rCSI 1.6%PRS 61.7%
-
CSI 1.8rCSI 5.7%PRS 43.6%
-
CSI 1.9rCSI 2.1%PRS 76.6%
-
CSI 1.9rCSI 3.5%PRS 48.7%
-
CSI 1.9rCSI 2.4%PRS 70.6%
-
CSI 1.9rCSI 11.9%PRS 52.2%
-
CSI 1.9rCSI 4.2%PRS 64.5%
-
CSI 1.9rCSI 1.6%PRS 61.5%
-
CSI 1.9rCSI 1.7%PRS 70.9%
-
CSI 2.0rCSI 3.5%PRS 57.2%
-
CSI 2.0rCSI 1.6%PRS 47.1%
-
CSI 2.0rCSI 4.0%PRS 77.9%
-
CSI 2.1rCSI 6.9%PRS 45.6%
-
CSI 2.1rCSI 1.7%PRS 66.9%
-
CSI 2.1rCSI 4.2%PRS 49.3%
-
CSI 2.2rCSI 2.0%PRS 60.6%
-
CSI 2.2rCSI 3.3%PRS 65.5%
-
CSI 2.2rCSI 2.6%PRS 79.0%
-
CSI 2.2rCSI 6.6%PRS 63.3%
-
CSI 2.3rCSI 3.9%PRS 50.4%
-
CSI 2.3rCSI 2.9%PRS 40.2%
-
CSI 2.3rCSI 2.0%PRS 70.0%
-
CSI 2.3rCSI 3.7%PRS 62.4%
-
CSI 2.3rCSI 3.8%PRS 49.5%
-
CSI 2.4rCSI 1.6%PRS 73.3%
-
CSI 2.4rCSI 1.7%PRS 52.8%
-
CSI 2.4rCSI 8.9%PRS 52.3%
-
CSI 2.4rCSI 3.9%PRS 65.6%
-
CSI 2.4rCSI 3.3%PRS 52.0%
-
CSI 2.4rCSI 5.4%PRS 42.9%
-
CSI 2.5rCSI 2.4%PRS 76.0%
-
CSI 2.5rCSI 3.0%PRS 69.0%
-
CSI 2.5rCSI 14.4%PRS 59.0%
-
CSI 2.6rCSI 1.7%PRS 80.4%
-
CSI 2.6rCSI 3.1%PRS 67.7%
-
CSI 2.6rCSI 6.0%PRS 60.0%
-
CSI 2.7rCSI 4.2%PRS 52.9%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 3893795032
Symbol: MD1L1_HUMAN
Name: Mitotic spindle assembly checkpoint protein MAD1
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9546394
Title: Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1.
PubMed ID: 9546394
PubMed ID: 10198256
Title: Phosphorylation of human MAD1 by the BUB1 kinase in vitro.
PubMed ID: 10198256
PubMed ID: 10049595
Title: Mitotic checkpoint locus MAD1L1 maps to human chromosome 7p22 and mouse chromosome 5.
PubMed ID: 10049595
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 12853948
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 14978040
Title: NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling.
PubMed ID: 14978040
PubMed ID: 16964243
Title: A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
PubMed ID: 16964243
DOI: 10.1038/nbt1240
PubMed ID: 17525332
Title: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
PubMed ID: 17525332
PubMed ID: 19010891
Title: Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer.
PubMed ID: 19010891
PubMed ID: 18981471
Title: Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint.
PubMed ID: 18981471
DOI: 10.1101/gad.1677208
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19273613
Title: Spatiotemporal control of mitosis by the conserved spindle matrix protein Megator.
PubMed ID: 19273613
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 20133940
Title: Nucleoporin translocated promoter region (Tpr) associates with dynein complex, preventing chromosome lagging formation during mitosis.
PubMed ID: 20133940
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 22351768
Title: RED, a spindle pole-associated protein, is required for kinetochore localization of MAD1, mitotic progression, and activation of the spindle assembly checkpoint.
PubMed ID: 22351768
PubMed ID: 22223895
Title: Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.
PubMed ID: 22223895
PubMed ID: 22814378
Title: N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
PubMed ID: 22814378
PubMed ID: 24374861
Title: Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma.
PubMed ID: 24374861
DOI: 10.1002/path.4319
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 25218447
Title: Uncovering global SUMOylation signaling networks in a site-specific manner.
PubMed ID: 25218447
DOI: 10.1038/nsmb.2890
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
PubMed ID: 29162720
Title: Direct interactions of mitotic arrest deficient 1 (MAD1) domains with each other and MAD2 conformers are required for mitotic checkpoint signaling.
PubMed ID: 29162720
PubMed ID: 12006501
Title: Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint.
PubMed ID: 12006501
PubMed ID: 10366450
Title: Characterization of MAD2B and other mitotic spindle checkpoint genes.
PubMed ID: 10366450
PubMed ID: 10597320
Title: Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers.
PubMed ID: 10597320
PubMed ID: 11423979
Title: Mutations in the mitotic check point gene, MAD1L1, in human cancers.
PubMed ID: 11423979
PubMed ID: 36322655
Title: Biallelic germline mutations in MAD1L1 induce a syndrome of aneuploidy with high tumor susceptibility.
PubMed ID: 36322655
Sequence Information:
- Length: 718
- Mass: 83067
- Checksum: DA65529856A37EE3
- Sequence:
MEDLGENTMV LSTLRSLNNF ISQRVEGGSG LDISTSAPGS LQMQYQQSMQ LEERAEQIRS KSHLIQVERE KMQMELSHKR ARVELERAAS TSARNYEREV DRNQELLTRI RQLQEREAGA EEKMQEQLER NRQCQQNLDA ASKRLREKED SLAQAGETIN ALKGRISELQ WSVMDQEMRV KRLESEKQEL QEQLDLQHKK CQEANQKIQE LQASQEARAD HEQQIKDLEQ KLSLQEQDAA IVKNMKSELV RLPRLERELK QLREESAHLR EMRETNGLLQ EELEGLQRKL GRQEKMQETL VGLELENERL LAKLQSWERL DQTMGLSIRT PEDLSRFVVE LQQRELALKD KNSAVTSSAR GLEKARQQLQ EELRQVSGQL LEERKKRETH EALARRLQKR VLLLTKERDG MRAILGSYDS ELTPAEYSPQ LTRRMREAED MVQKVHSHSA EMEAQLSQAL EELGGQKQRA DMLEMELKML KSQSSSAEQS FLFSREEADT LRLKVEELEG ERSRLEEEKR MLEAQLERRA LQGDYDQSRT KVLHMSLNPT SVARQRLRED HSQLQAECER LRGLLRAMER GGTVPADLEA AAASLPSSKE VAELKKQVES AELKNQRLKE VFQTKIQEFR KACYTLTGYQ IDITTENQYR LTSLYAEHPG DCLIFKATSP SGSKMQLLET EFSHTVGELI EVHLRRQDSI PAFLSSLTLE LFSRQTVA